WO1996021416A3 - Methods and compositions for treatment of solid tumors in vivo - Google Patents

Methods and compositions for treatment of solid tumors in vivo Download PDF

Info

Publication number
WO1996021416A3
WO1996021416A3 PCT/US1995/016855 US9516855W WO9621416A3 WO 1996021416 A3 WO1996021416 A3 WO 1996021416A3 US 9516855 W US9516855 W US 9516855W WO 9621416 A3 WO9621416 A3 WO 9621416A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
treatment
methods
blood
solid tumors
Prior art date
Application number
PCT/US1995/016855
Other languages
French (fr)
Other versions
WO1996021416A2 (en
Inventor
Francis J Burrows
Timothy C Fong
John M Polo
Thomas W Dubensky Jr
Douglas J Jolly
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to JP52168596A priority Critical patent/JP2001520503A/en
Priority to EP95944229A priority patent/EP0802801A2/en
Priority to AU46082/96A priority patent/AU4608296A/en
Publication of WO1996021416A2 publication Critical patent/WO1996021416A2/en
Publication of WO1996021416A3 publication Critical patent/WO1996021416A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

The present invention provides compositions and methods for treatment of solid tumors with gene therapy utilizing recombinant viral vectors that express polypeptides which selectively initiate irreversible coagulation of blood in the tumor vasculature, inhibit tumor neovascularization, are capable of activating a non-toxic agent into a toxic agent within the tumor vascular wall causing destruction of the vascular bed and absorb or metabolize nutrients in the blood being supplied to the tumor. The production of these polypeptides by transduced cells in or adjacent to the blood vessels of the tumor result in the death of tumor cells.
PCT/US1995/016855 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo WO1996021416A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52168596A JP2001520503A (en) 1994-12-30 1995-12-22 Methods and compositions for the treatment of solid tumors in vivo
EP95944229A EP0802801A2 (en) 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo
AU46082/96A AU4608296A (en) 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36857494A 1994-12-30 1994-12-30
US08/368,574 1994-12-30

Publications (2)

Publication Number Publication Date
WO1996021416A2 WO1996021416A2 (en) 1996-07-18
WO1996021416A3 true WO1996021416A3 (en) 1996-10-10

Family

ID=23451821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016855 WO1996021416A2 (en) 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo

Country Status (4)

Country Link
EP (1) EP0802801A2 (en)
JP (1) JP2001520503A (en)
AU (1) AU4608296A (en)
WO (1) WO1996021416A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113990A1 (en) * 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
ATE340259T1 (en) * 1996-07-16 2006-10-15 Archibald James Mixson CATIONIC VEHICLE: DNA COMPLEXES AND THEIR USE IN GENE THERAPY
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
WO1998012332A1 (en) * 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
FR2757178B1 (en) * 1996-12-13 1999-03-05 Centre Nat Rech Scient USE OF A VECTOR EXPRESSING DNA POLYMERASE BETA AS A MEDICAMENT
DE19701141C1 (en) * 1997-01-16 1998-04-09 Hoechst Ag Gene construct for treatment of disease involving protease, particularly tumours and inflammation
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
AU2006302794B2 (en) 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
ES2620702B2 (en) * 2017-03-29 2017-12-18 Universidad De Cantabria Gene construction and its use in the treatment of cardiac fibrosis

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292763A2 (en) * 1987-05-19 1988-11-30 Hoechst Aktiengesellschaft Gene-technological process for the preparation of angiogenines
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
FR2683226A1 (en) * 1991-10-30 1993-05-07 Univ Paris Curie CELLS TRAPED AGAINST ANTIGENS CAUSING DYSFUNCTION OF THE IMMUNE SYSTEM, MEDICINES FOR THE PREVENTION OR TREATMENT OF DISEASES INDUCED BY SUCH DYSFUNCTIONS.
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
WO1993018185A1 (en) * 1992-03-03 1993-09-16 The Salk Institute For Biological Studies Receptor internalization signals
WO1993018794A1 (en) * 1992-03-26 1993-09-30 Gensia, Inc. In vivo peptide therapy
WO1994013823A1 (en) * 1992-12-10 1994-06-23 Z. Company S.A. Nucleotide sequence for treating cancer and infection
WO1994021118A1 (en) * 1993-03-24 1994-09-29 The Uab Research Foundation Gene-therapy composition and method for treating carcinomas

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
EP0292763A2 (en) * 1987-05-19 1988-11-30 Hoechst Aktiengesellschaft Gene-technological process for the preparation of angiogenines
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
FR2683226A1 (en) * 1991-10-30 1993-05-07 Univ Paris Curie CELLS TRAPED AGAINST ANTIGENS CAUSING DYSFUNCTION OF THE IMMUNE SYSTEM, MEDICINES FOR THE PREVENTION OR TREATMENT OF DISEASES INDUCED BY SUCH DYSFUNCTIONS.
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
WO1993018185A1 (en) * 1992-03-03 1993-09-16 The Salk Institute For Biological Studies Receptor internalization signals
WO1993018794A1 (en) * 1992-03-26 1993-09-30 Gensia, Inc. In vivo peptide therapy
WO1994013823A1 (en) * 1992-12-10 1994-06-23 Z. Company S.A. Nucleotide sequence for treating cancer and infection
WO1994021118A1 (en) * 1993-03-24 1994-09-29 The Uab Research Foundation Gene-therapy composition and method for treating carcinomas

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BELLELLI ET AL: "INHIBITION OF SPONTANEOUS METASTASES OF LEWIS LUNG CARCINOMA IN MICE TRANSGENIC FOR THE PLASMINOGEN ACTIVATOR INHIBITOR 1", CLINICAL AND EXPERIMENTAL METASTASIS, vol. 12, no. 5, September 1994 (1994-09-01), pages 13, XP000569390 *
BROOKS ET AL: "REQUIREMENT OF VASCULAR INTEGRIN ALPHAVBETA3 FOR ANGIOGENESIS", SCIENCE, vol. 264, 22 April 1994 (1994-04-22), pages 569 - 571, XP002010522 *
DECLERCK ET AL: "INHIBITION OF INVASION AND METASTASIS IN CELLS TRANSFECTED WITH AN INHIBITOR OF METALLOPROTEINASES", CANCER RESEARCH, vol. 52, 1 February 1992 (1992-02-01), pages 701 - 708, XP002010519 *
FREEMAN ET AL: "THE 'BYSTANDER EFFECT':TUMOR REGRESSION WHEN A FRACTION OF THE TUMOR MASS IS GENETICALLY MODIFIED", CANCER RESEARCH, vol. 53, 1 November 1993 (1993-11-01), pages 5274 - 5283, XP002010521 *
MONTGOMERY ET AL: "EFFECT OF TISSUE INHIBITOR OF THE MATRIX METALLOPROTEINASES -2 EXPRESSION ON THE GROWTH AND SPONTANEOUS METASTASIS OF A HUMAN MELANOMA CELL LINE", CANCER RESEARCH, vol. 54, 15 October 1994 (1994-10-15), pages 5467 - 5473, XP002010520 *
ROEMER ET AL: "CONCEPTS AND STRATEGIES FOR HUMAN GENE THERAPY", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 208, no. 2, September 1992 (1992-09-01), pages 211 - 225, XP002003648 *
TJUVAJEV ET AL: "OVEREXPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR 2 IN TUMOR CELLS INHIBITS TUMOR GROWTH,BLOOD BRAIN BARRIER PERMEABILITY,AND GLUCOSE METABOLISM", PROCEEDINGS OF THE AMERICAN ASSOCATION FOR CANCER RESEARCH, vol. 36, March 1995 (1995-03-01), pages 93, XP002003647 *
VALENTE ET AL: "INHIBITION OF INVASION AND TUMOR-ASSOCIATED IN VITRO ANGIOGENESIS BY TIMP-2 TRANSFECTION OF B16-F10 MELANOMA CELLS", CLINICAL AND EXPERIMENTAL METASTASIS, vol. 12, no. 5, September 1994 (1994-09-01), pages 13 - 14, XP000578196 *
WEITMAN ET AL: "DISTRIBUTION OF THE FOLATE RECEPTOR GP38 IN NORMAL AND MALIGNANT CELL LINES AND TISSUES", CANCER RESEARCH, vol. 52, 15 June 1992 (1992-06-15), pages 3396 - 3401, XP002010523 *

Also Published As

Publication number Publication date
AU4608296A (en) 1996-07-31
WO1996021416A2 (en) 1996-07-18
EP0802801A2 (en) 1997-10-29
JP2001520503A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
WO1996021416A3 (en) Methods and compositions for treatment of solid tumors in vivo
ATE199741T1 (en) GENE THERAPEUTICAL TREATMENT OF TUMORS WITH AN ENDOTHELIAL CELL-SPECIFIC, CELL CYCLE-DEPENDENT ACTIVE SUBSTANCE
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL141141A0 (en) Targeting pharmaceutical agents to injured tissues
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002058534A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
WO2003035688A3 (en) Targeted thrombosis by tissue factor polypeptides
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
WO1999040945A3 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1961819A3 (en) Composition and methods for the therapy and diagnosis of lung cancer
CA2162732A1 (en) Use of modified tall-104 cells to treat cancer and viral diseases
WO2001094409A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
EP1351967A4 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1995944229

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995944229

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995944229

Country of ref document: EP